Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum

被引:164
作者
Healy, CM
Munoz, FM
Rench, MA
Halasa, NB
Edwards, KM
Baker, CJ
机构
[1] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol Virol & Microbiol, Infect Dis Sect, Houston, TX 77030 USA
[3] Vanderbilt Univ, Sch Med, Dept Pediat, Div Infect Dis, Nashville, TN USA
关键词
D O I
10.1086/421033
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Passively acquired maternal antibodies protect infants from many pathogens. With increasing reports of infant pertussis, we evaluated pertussis antibodies in maternal-infant paired sera from 1999 - 2000. Methods. Antibodies to pertussis toxin ( PT), filamentous hemagglutinin (FHA), and fimbrial proteins (FIM) were measured by validated IgG-specific enzyme-linked immunosorbant assay ( ELISA) in 64 maternal - umbilical cord serum pairs and in 61 of 64 infant sera. Geometric mean concentrations (GMCs) of pertussis antibodies and cord: maternal GMC ratios were calculated. Results. Mean maternal age and gestation were 29.7 years ( range, 19 - 42) and 39.3 weeks ( range, 35.6 - 40.9), and 81% of mothers were white. GMCs of maternal antibodies at delivery ( ELISA units/mL) were 2.4 for PT, 6.9 for FHA, and 13 for FIM. Cord GMCs were 169%, 178%, and 157% of maternal delivery values for PT, FHA, and FIM, respectively, demonstrating active placental transfer (P < .001). Pertussis-specific IgG values for each antigen decayed to below the threshold of detection by age 2 months. Conclusions. Despite efficient placental transfer, low maternal pertussis antibody levels and their rapid decay in infant sera leave infants with little humoral protection against pertussis. These data support the rationale for maternal or neonatal immunization, with acellular pertussis vaccines, to prevent life-threatening pertussis in early infancy.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 47 条
  • [1] Andrews R, 1997, Commun Dis Intell, V21, P145
  • [2] Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine
    Baker, CJ
    Rench, MA
    McInnes, P
    [J]. VACCINE, 2003, 21 (24) : 3468 - 3472
  • [3] BARAFF LJ, 1984, PEDIATRICS, V73, P37
  • [4] Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination
    Baron, S
    Njamkepo, E
    Grimprel, E
    Begue, P
    Desenclos, JC
    Drucker, J
    Guiso, N
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (05) : 412 - 418
  • [5] BEITER A, 1993, OBSTET GYNECOL, V82, P691
  • [6] Immunogenicity of a three-component acellular pertussis vaccine administered at birth
    Belloni, C
    De Silvestri, A
    Tinelli, C
    Avanzini, MA
    Marconi, M
    Strano, F
    Rondini, G
    Chirico, G
    [J]. PEDIATRICS, 2003, 111 (05) : 1042 - 1045
  • [7] The seroepidemiology of Bordetella pertussis infections: A study of persons ages 1-65 years
    Cattaneo, LA
    Reed, GW
    Haase, DH
    Wills, MJ
    Edwards, KM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (05) : 1256 - 1259
  • [8] The science and fiction of the "resurgence" of pertussis
    Cherry, JD
    [J]. PEDIATRICS, 2003, 112 (02) : 405 - 406
  • [9] The placental transmission of protective antibodies a gainst whooping cough - By inoculation of the pregnant mother
    Cohen, P
    Scadron, SJ
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1943, 121 : 656 - 662
  • [10] Deaths from pertussis are underestimated in England
    Crowcroft, NS
    Andrews, N
    Rooney, C
    Brisson, M
    Miller, E
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (05) : 336 - 338